Dr. Hutcheon's major areas of research interest are the diagnosis and treatment of acute and chronic venous thromboembolism with a special interest in hypercoaguable states, and incorporating evidence-based medicine into quality improvement and cost-conscious decision making in internal medicine residency training. Dr. Hutcheon is also passionate about teaching residents how to initiate effective end-of-life and goals-of-care discussions.
Dr. Hutcheon earned his medical degree from Case Western Reserve University School of Medicine. He then went on to complete his internship and residency from University of Pittsburgh Medical Center on the Internal Medicine-Clinical Scientist Track.
Occidental College Department of Chemistry: Analytical Chemistry Award, 2001
Occidental College: Presidential Scholarship, 1998-2002
Case Western Reserve University: Dean's Scholarship, 2007-2011
Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51. View in: PubMed
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 1; 110(3):556-63. View in: PubMed